Proliferation News and Research

RSS

New discovery in glioma-associated metabolic changes

Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome", in The Proceedings of the National Academy of Sciences.

3 Mar 2011

Turmeric may be 'the right spice' to fight colon cancer

Turmeric, a bright yellow spice from south Asia belonging to the ginger family, is the main ingredient in curries - and ancient wisdom suggests that it's also good for your health. Taking this wisdom to the laboratory, Tel Aviv University researchers have discovered that turmeric's active ingredient called curcumin amplifies the therapeutic activity of highly toxic anti-inflammatory drugs used to fight colon cancer when used at high doses.

3 Mar 2011

Virostatics' VS411 Phase 2a trial results against HIV presented at 18th CROI

An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.

2 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

Bioanalysis accepted for coverage by EMBASE & Scopus

EMBASE is a premier online resource for biomedical literature, with over 24 million indexed records and more than 7,500 current, mostly peer-reviewed journals, EMBASE quickly and accurately delivers biomedical answers. Scopus is the largest abstract and citation database of research literature and quality web sources covering nearly 18,000 titles from more than 5,000 publishers.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

IPG Photonics fourth quarter revenues increase 86% year-over-year to $101 million

IPG Photonics Corporation today reported financial results for the fourth quarter of fiscal 2010 ended December 31, 2010.

25 Feb 2011

Western Digital establishes new HDD research and development center in Singapore

Western Digital announced today that it has established a research and development center in Singapore, where the company will leverage the local talent pool and expertise of research organizations, such as Singapore's A*STAR Data Storage Institute, and universities in the development of advanced hard drive technologies.

25 Feb 2011

Progeria-derived iPS cells may treat aging-related disease in children

The current pace of population aging is without parallel in human history but surprisingly little is known about the human aging process, because lifespans of eight decades or more make it difficult to study. Now, researchers at the Salk Institute for Biological Studies have replicated premature aging in the lab, allowing them to study aging-related disease in a dish.

24 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

New research demonstrates how climate change can increase exposure, risk of human illness

A panel of scientists speaking today at the annual meeting of the American Association for the Advancement of Science unveiled new research and models demonstrating how climate change could increase exposure and risk of human illness originating from ocean, coastal and Great Lakes ecosystems, with some studies projecting impacts to be felt within 30 years.

20 Feb 2011

Platelet-rich fibrin matrix doesn't improve healing after rotator cuff repair

For years, doctors have used platelet rich plasma (PRP) to promote healing in various surgeries, but a recent study demonstrates that a type of PRP did not improve healing after rotator cuff repair.

18 Feb 2011

Two studies investigate frontiers of islet cell transplantation for treating diabetes

Two studies published in the current issue of Cell Transplantation investigate frontiers of islet cell transplantation for treating diabetes. Researchers in Milan, Italy re-examine the role of bone marrow stem cells in diabetic therapy and islet cell regeneration and Canadian researchers offer improved strategies for optimizing pancreatic islet culture in vitro.

18 Feb 2011

Radio frequency exposure from mobile phones does not appear to increase risk of brain cancer

Radio frequency exposure from mobile phone use does not appear to increase the risk of developing brain cancers by any significant amount, a study by University of Manchester scientists suggests.

17 Feb 2011

Study: Active wound healing can lead to increased risk of basal cell carcinoma in skin

Processes that are involved in active wound healing can lead to an increased risk for basal cell carcinoma in the skin. This is the conclusion of a recent study from the Swedish medical university Karolinska Institutet, published in the journal PNAS.

15 Feb 2011

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

PsychoGenics today announced the establishment of an alliance with KineMed, to provide specialized neurogenesis services to complement PsychoGenics' in vivo testing capabilities.

15 Feb 2011

Oestrogen reduces risk of breast cancer: Study

A team of researchers at CIC bioGUNE has revealed that oestrogen can reduce the risk of breast cancer. Their work shows that oestrogen is capable of reducing the number of breast cancer stem cells, which may explain the lower aggression of the tumour and, as a consequence, the possibility of a better prognosis.

14 Feb 2011

Scientists develop novel treatment strategy for multiple myeloma

Scientists at Virginia Commonwealth University Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The study's findings, published in today's edition of the journal "Blood," are the first to demonstrate the synergistic, anti-myeloma effects of this combination regimen both in vitro and in vivo.

11 Feb 2011

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Myriad Genetics, Inc. announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome.

10 Feb 2011